Products for Research Use Only
RegisterLogin

Mirdametinib (GMP)

CAT: 0804-HY-10254G-01Size: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10254G-01Size:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mirdametinib (PD0325901) (GMP) is Mirdametinib produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor[1][2][3].
CAS Number
391210-10-9
Product Name Alternative
PD0325901 (GMP) ; PD325901 (GMP)
UNSPSC
12352005
Hazard Statement
H301, H373, H413
Target
MEK
Type
GMP Small Molecules
Related Pathways
MAPK/ERK Pathway
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/mirdametinib-gmp.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC=C(C(F)=C1NC2=CC=C(I)C=C2F)F)NOC[C@H](O)CO
Molecular Formula
C16H14F3IN2O4
Molecular Weight
482.19
Precautions
H301, H373, H413
References & Citations
[1]Avolio E, et al. Cardiac pericyte reprogramming by MEK inhibition promotes arteriologenesis and angiogenesis of the ischemic heart. J Clin Invest. 2022 May 16;132 (10) :e152308.|[2]Suo N, et al. Inhibition of MAPK/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases. Glia. 2019 Jul;67 (7) :1320-1332.|[3]Ai Z, et al. Maintenance of Self-Renewal and Pluripotency in J1 Mouse Embryonic Stem Cells through Regulating Transcription Factor and MicroRNA Expression Induced by PD0325901. Stem Cells Int. 2016;2016:1792573.
Shipping Conditions
Blue Ice
Storage Conditions
Keep sealed and protect from light, store at 2-8°C
Scientific Category
GMP Small Molecules
Clinical Information
Phase 2
Citation 01
BioRxiv. 2025 Nov 12.|Andrology. 2025 Jun 16.|Animals (Basel) . 2021 Feb 6;11 (2) :425.|Animals (Basel) . 2024 May 4;14 (9) :1382.|Biochem Biophys Res Commun. 2020 Apr 2;524 (2) :280-287.|Biochem Biophys Res Commun. 2022 Jan 29:590:125-131.|Biochem Biophys Res Commun. 2023 Jan 29:642:145-153.|Biol Reprod. 2024 May 9;110 (5) :950-970.|Biomaterials. 2018 Oct;180:12-23.|Bioorg Chem. 2023 Mar:132:106321.|Bioorg Med Chem. 2023 Jul 15:90:117366.|bioRxiv. 2019 Sep.|bioRxiv. 2023 Aug 14.|bioRxiv. 2023 Jun 15:2023.06.15.545148.|bioRxiv. 2024 Apr 2.|bioRxiv. 2024 Aug 31:2024.08.29.610385.|bioRxiv. 2024 Dec 10:2024.12.09.627542.|bioRxiv. 2024 Dec 6:2024.12.06.627179.|bioRxiv. 2024 Feb 27.|bioRxiv. 2024 Mar 12.|bioRxiv. 2025 Feb 2:2025.02.01.636075.|bioRxiv. 2025 January 18.|bioRxiv. 2025 January 28.|bioRxiv. 2025 March 21.|bioRxiv. 2025 Nov 20:2025.11.20.689490.|bioRxiv. 2025 Oct 14.|bioRxiv. 2025 Oct 17.|bioRxiv. 2025 Sep 5.|Blood Adv. 2023 Jul 11;7 (13) :3199-3212.|Brain Res Bull. 2019 Oct:152:285-296.|Cancer Cell Int. 2021 Jun 5;21 (1) :291.|Cancer Lett. 2019 Feb 1:442:202-212.|Cancers (Basel) . 2022 Oct 31;14 (21) :5368.|Cell Death Dis. 2021 Oct 30;12 (11) :1034.|Cell Death Dis. 2022 Mar 30;13 (3) :284.|Cell Death Discov. 2021 Oct 2;7 (1) :271.|Cell Prolif. 2022 Apr;55 (4) :e13209.|Cell Prolif. 2023 Dec;56 (12) :e13498.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2022 Mar 29;38 (13) :110570.|Cell Rep. 2025 Mar 5;44 (3) :115362.|Cell Stem Cell. 2022 Jul 7;29 (7) :1102-1118.e8.|Cell Stem Cell. 2025 Aug 29;32 (10) :1509-1527.e9|Cell Stem Cell. 2025 Mar 6;32 (3) :409-425.e8.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Cell Syst. 2020 Nov 18;11 (5) :478-494.e9.|Cell. 2024 Nov 14;187 (23) :6566-6583.e22.|Cell. 2025 Oct 30;188 (22) :6301-6316.e29.|Chem Biol. 2012 Jan 27;19 (1) :140-54.|Chem Eng J. 2024 Sep 1.|Clin Cancer Res. 2014 Nov 1;20 (21) :5483-95. |Clin Cancer Res. 2020 Apr 15;26 (8) :2011-2021. |Comput Biol Med. 2025 Jul 5;196 (Pt A) :110721.|Curr Protoc Cell Biol. 2018 Dec;81 (1) :e62.|Dev Cell. 2025 Jul 21;60 (14) :2007-2022.e7.|EMBO Rep. 2022 Feb 3;23 (3) :e53191.|Environ Int. 2025 Sep 28:204:109820.|Epilepsy Res. 2022 Mar:181:106890.|Eur J Pharm Sci. 2021 Dec 1:167:106003.|Exp Cell Res. 2023 Jun 15;427 (2) :113603.|FEBS Open Bio. 2021 Oct;11 (10) :2740-2755.|FEBS Open Bio. 2025 Sep 10.|Front Cell Dev Biol. 2018 Sep 25:6:111.|Front Neurosci. 2022 Jun 7;16:901688.|Fundam Clin Pharmacol. 2020 Oct;34 (5) :571-580.|Gene. 2025 Jan 15:933:148985.|Genes (Basel) . 2024 Oct 30;15 (11) :1400.|Genome Biol. 2025 Jul 7;26 (1) :196.|Glia. 2019 Jul;67 (7) :1320-1332. |Harvard Medical School LINCS LIBRARY|Int Immunopharmacol. 2021 Apr:93:107395.|Int J Mol Sci. 2024 Sep 21;25 (18) :10138.|Int J Mol Sci. 2025 Jun 16;26 (12) :5758.|iScience. 2023 Jul 26;26 (8) :107469.|J Anim Sci. 2024 Jan 3:102:skae251.|J Biol Chem. 2012 Mar 23;287 (13) :9742-52.|J Biol Chem. 2020 Oct 16;295 (42) :14325-14342.|J Exp Clin Cancer Res. 2018 Feb 20;37 (1) :32. |J Exp Clin Cancer Res. 2018 Jun 28;37 (1) :128. |J Exp Clin Cancer Res. 2025 Nov 6;44 (1) :300.|J Hazard Mater. 2023 Oct 5:459:132225.|J Invest Dermatol. 2022 Mar;142 (3 Pt A) :613-623.e7.|JCI Insight. 2025 Sep 23;10 (18) :e190716.|Lung Cancer. 2025 Nov 19:211:108848.|Lwt-Food Sci Technol. 11 Oct 2021.|Nat Biomed Eng. 2018 Aug;2 (8) :578-588.|Nat Commun. 2022 Nov 29;13 (1) :7345.|Nat Commun. 2024 Dec 12;15 (1) :10476.|Nat Commun. 2024 Sep 5;15 (1) :7758.|Nat Commun. 2025 Jul 1;16 (1) :5540.|Nat Commun. 2025 Mar 17;16 (1) :2635.|Nat Immunol. 2025 Oct;26 (10) :1673-1685.|Nat Methods. 2025 Mar;22 (3) :510-519.|Nat Protoc. 2023 May;18 (5) :1584-1620.|Nat Struct Mol Biol. 2025 Sep 1.|Nature. 2022 Jan;601 (7894) :600-605.|Nature. 2025 Jan;637 (8046) :726-735. |Neuro Oncol. 2019 Mar 18;21 (4) :486-497. |Neuroscience. 2024 May 9:S0306-4522 (24) 00196-9.|Nucleic Acids Res. 2021 Nov 18;49 (20) :11575-11595.|Oncotarget. 2020 Nov 3;11 (44) :3921-3932.|Patent. US20140309249A1.|Patent. US20160368910A1.|Patent. US20180263995A1.|Patent. US20190248778A1.|Patent. US20240307414A1.|PeerJ. 2020 Oct 2;8:e9981.|Platelets. 2022 Jul 4;33 (5) :755-763.|Preprints. 2023 May 5.|Proc Natl Acad Sci U S A. 2019 Jun 18;116 (25) :12147-12152.|Redox Biol. 2025 Apr:81:103539.|Research Square Preprint. 2022 Feb.|Research Square Print. October 21st, 2022.|Sci China Life Sci. 2025 Jul;68 (7) :2058-2072.|Sci Data. 2024 Sep 19;11 (1) :1024.|Sci Rep. 2025 Nov 17;15 (1) :40227.|Sci Signal. 2021 Jun 22;14 (688) :eabe6156.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Signal Transduct Target Ther. 2024 Mar 9;9 (1) :65.|SSRN. 2023 Sep 1.|SSRN. 2025 Apr 24.|SSRN. 2025 May 27.|STAR Protoc. 2021 Nov 5;2 (4) :100881.|STAR Protoc. 2023 Feb 3;4 (1) :102092.|STAR Protoc. 2023 Mar 16;4 (2) :102151.|Stem Cell Reports. 2025 Jan 23:102398.|Stem Cell Res Ther. 2024 Dec 18;15 (1) :473.|Stem Cell Res Ther. 2025 Oct 8;16 (1) :547.|Stem Cells Int. 2018 Dec 25:2018:5965727.|Stem Cells Int. 2020 Feb 3;2020:8483035.|Stem Cells Transl Med. 2021 May;10 (5) :743-755.|Stem Cells. 2022 Oct 21;40 (10) :892-905.|Toxicon. 2026 Jan:269:108660.|Transl Oncol. 2023 Mar:29:101628.|Universidad Del Pais Vasco. 2023 Jun 22.|Virology. 2020 Jan 2;539:121-128.|Viruses. 2018 Apr 13;10 (4) . pii: E191.

Related Products

CatalogName
HY-10254-01Mirdametinib
HY-N0737AG-01Harmine (GMP)
HY-N0083GBetulin (GMP)
HY-15682G-01TTNPB (GMP)
HY-15794GNemorubicin (GMP)
HY-13506G-01M344 (GMP)
HY-10219G-01Rapamycin (GMP)
HY-107632GGYY4137 (GMP)
HY-10227GBortezomib (GMP)
HY-101570GNedisertib (GMP)

Alternative Products

CatalogName
WGC308083-5mgMirdametinib
C07457-100mgMirdametinib (PD0325901)
A10256-500Mirdametinib (PD0325901) 500mg
A10256-25Mirdametinib (PD0325901) 25mg
A10256-1000Mirdametinib (PD0325901) 1g
A10256-10Mirdametinib (PD0325901) 10mg
A10256-100Mirdametinib (PD0325901) 100mg
A10256-50Mirdametinib (PD0325901) 50mg
A10256-200Mirdametinib (PD0325901) 200mg
A10256-5Mirdametinib (PD0325901) 5mg

Popular Products